Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins

Journal of Clinical Oncology

Volumn 17, Issue 2, 1999, Pages 569-577

  Smith, Malcolm A ^a   Rubinstein, Lawrence ^a   Anderson, James R ^a   Arthur, Diane ^a   Catalano, Paul J ^a   Freidlin, Boris ^a   Heyn, Ruth ^a   Khayat, Anita ^a   Krailo, Mark ^a   Land, Vita J ^a   Miser, James ^a   Shuster, Jonathan ^a   Vena, Don ^a  

^a EMMES CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; DOXORUBICIN; EPIPODOPHYLLOTOXIN; ETOPOSIDE; GYRASE INHIBITOR; TENIPOSIDE;

ACUTE LYMPHOCYTIC LEUKEMIA; ARTICLE; CANCER INCIDENCE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; DRUG INDUCED CANCER; DRUG MONITORING; DRUG SAFETY; DRUG SCREENING; FOLLOW UP; HUMAN; LEUKEMIA; MAJOR CLINICAL STUDY; META ANALYSIS; MULTICENTER STUDY; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; RISK ASSESSMENT; SOLID TUMOR;

EID: 0033008437     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.2.569     Document Type: Article

References (58)

1. Pedersen-Bjergaard J, Rowley J: The balanced and the unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute differently to malignant transformation. Blood 83:2780-2786, 1994
2. Smith M, Rubinstein L, Ungerleider R: Therapy-related acutemyeloid leukemia following treatment with epipodophyllotoxins: Estimating the risks. Med Pediatr Oncol 23:86-98, 1994
3. Pui CH, Behm FG, Raimondi SC, et al: Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia [see comments]. N Engl J Med 321:136-142, 1989
4. Pui CH, Ribeiro RC, Hancock ML, et al: Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med 325:1682-1687, 1991
5. Pui C-H, Relling M, Rivera G, et al: Characteristics and outcome of epipodophyllotoxin-related acute myeloid leukemia. Blood 86:267a, 1995 (abstr)
6. Winick NJ, McKenna RW, Shuster JJ, et al: Secondary acute myeloid leukemia in children with acute lymphoblastic leukemia treated with etoposide [see comments]. J Clin Oncol 11:209-217, 1993
7. Amylon M, Carroll A, Link M, et al: Second malignancies in children treated with teniposide (VM-26) for T-cell lymphoid malignancy: A role for asparaginase? A Pediatric Oncology Group Study. Blood 80:206a, 1992 (abstr)
8. Katz JA, Shuster JJ, Ravindranath Y, et al: Secondary acute myelogenous leukemia (AML) following intensive treatment for childhood T-cell acute lymphoblastic leukemia (T-ALL) and advanced stage lymphoblastic lymphoma (LL) treated with teniposide (VM-26): A Pediatric Oncology Group (POG) study. Proc Am Soc Clin Oncol 14:344, 1995 (abstr)
9. Bokemeyer C, Schmoll HJ, Kuczyk MA, et al: Risk of secondary leukemia following high cumulative doses of etoposide during chemotherapy for testicular cancer. J Natl Cancer Inst 87:58-60, 1995 (letter)
10. Bokemeyer C, Schmoll H-J: Treatment of testicular cancer and the development of secondary malignancies. J Clin Oncol 13:283-292, 1995
11. Boshoff C, Begent R, Oliver R, et al: Secondary tumors following etoposide containing therapy for germ cell cancer. Ann Oncol 6:35-40, 1995
12. Bajorin D, Motzer R, Rodriguez E, et al: Acute nonlymphocytic leukemia in germ cell tumor patients treated with etoposide-containing chemotherapy. J Natl Cancer Inst 85:60-62, 1993
13. Grier H, Krailo M, Link M, et al: Improved outcome in nonmetastatic Ewing's sarcoma (EWS) and PNET of bone with the addition of ifosfamide (I) and etoposide (E) to vincristine (V), adriamycin (Ad), cyclophosphamide (C), and actinomycin (A): A Children's Cancer Group (CCG) and Pediatric Oncology Group (POG) report. Proc Am Soc Clin Oncol 13:421, 1994 (abstr)
14. Williams SD, Birch R, Einhorn LH, et al: Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 316:1435-1440, 1987
15. Cheung NV, Heller G: Chemotherapy dose intensity correlates strongly with response, median survival, and median progression-free survival in metastatic neuroblastoma [see comments]. J Clin Oncol 9:1050-1058, 1991
16. Smith M, Rubinstein L, Cazenave L, et al: Report of the Cancer Therapy Evaluation Program (CTEP) monitoring plan for secondary acute myeloid leukemia following treatment with epipodophyllotoxins. J Natl Cancer Inst 85:554-558, 1993
17. Mitelman FE (ed): ISCN (1995): An International System for Human Cytogenetic Nomenclature. Basel, Switzerland, S Karger, 1995
18. Fisher L, Van Bele G: Biostatistics: A Methodology for the Health Sciences, New York, NY, Wiley, 1993
19. Nichols C, Roth B, Heerema N, et al: Hematologic neoplasia associated with primary mediastinal germ-cell tumors. N Engl J Med 322:1425-1429, 1990
20. Ladanyi M, Samaniego F, Reuter VE, et al: Cytogenetic and immunohistochemical evidence for the germ cell origin of a subset of acute leukemias associated with mediastinal germ cell tumors. J Natl Cancer Inst 82:221-227, 1990
21. Orazi A, Neiman RS, Ulbright TM, et al: Hematopoietic precursor cells within the yolk sac tumor component are the source of secondary hematopoietic malignancies in patients with mediastinal germ cell tumors. Cancer 71:3873-881, 1993
22. Downie PA, Vogelzang NJ, Moldwin RL, et al: Establishment of a leukemia cell line with i(12p) from a patient with a mediastinal germ cell tumor and acute lymphoblastic leukemia. Cancer Res 54:4999-5004, 1994
23. Heyn R, Khan F, Ensign LG, et al: Acute myeloid leukemia in patients treated for rhabdomyosarcoma with cyclophosphamide and low-dose etoposide on Intergroup Rhabdomyosarcoma Study III: An interim report. Med Pediatr Oncol 23:99-106, 1994
24. Felix CA, Hosler MR, Winick NJ, et al: ALL-1 gene rearrangements in DNA topoisomerase II inhibitor-related leukemia in children. Blood 85:3250-3256, 1995
25. Pedersen-Bjergaard J: Acute promyelocytic leukemia with t(15; 17) following inhibition of DNA topoisomerase II [comment]. Ann Oncol 6:751-753, 1995 (editorial)
26. Naoe T, Kudo K, Yoshida H, et al: Molecular analysis of the t(15:17) translocation in de novo and secondary acute promyelocytic leukemia. Leukemia 11:287-288, 1997 (suppl 3)
27. Boice J, Greene M, Killen J, et al: Leukemia after adjuvant chemotherapy with semustine (methyl-CCNU): Evidence of a dose-response effect. N Engl J Med 314:119-120, 1986
28. Greene M, Harris E, Gershenson D, et al: Melphalan may be a more potent leukemogen than cyclophosphamide. Ann Intern Med 105:360-367, 1986
29. Meadows A, Obringer A, Marrero O, et al: Second malignant neoplasms following childhood Hodgkin's disease: Treatment and splenectomy as risk factors. Med Pediatr Oncol 17:477-484, 1989
30. Falkson G, Gelman R, Dreicer R, et al: Myelodysplastic syndrome and acute nonlymphocytic leukemia secondary to mitolactol treatment in patients with breast cancer. J Clin Oncol 7:1252-1259, 1989
31. Pedersen-Bjergaard J, Ersboll J, Sorensen H, et al: Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphoma. Ann Intern Med 103:195-200, 1985
32. Greene M, Boice J, Greer B, et al: Acute nonlymphocytic leukemia after therapy with alkylating agents for ovarian cancer: A study of five randomized clinical trials. N Engl J Med 307:1416-1421, 1982
33. Pedersen-Bjergaard J, Nissen N, Sorensen H, et al: Acute non-lymphocytic leukemia in patients with ovarian carcinoma following long-term treatment with Treosulfan (= dihydroxybusulfan). Cancer 45:19-29, 1980
34. Kaldor J, Day N, Clarke E, et al: Leukemia following Hodgkin's disease. N Engl J Med 322:7-13, 1990
35. Kaldor J, Day N, Pettersson F, et al: Leukemia following chemotherapy for ovarian cancer. N Engl J Med 322:1-6, 1990
36. Curtis RE, Boice JD Jr, Stovall M, et al: Risk of leukemia after chemotherapy and radiation treatment for breast cancer [see comments]. N Engl J Med 326:1745-1751, 1992
37. Kreissman S, Gelber R, Cohen H, et al: Incidence of secondary acute myelogenous leukemia after treatment of childhood acute lymphoblastic leukemia. Cancer 70:2208-2213, 1992
38. Sugita K, Furukawa T, Tsuchida M, et al: High frequency of etoposide (VP-16)-related secondary leukemia in children with non-Hodgkin's lymphoma. Am J Pediatr Hematol Oncol 15:99-104, 1993
39. Slevin ML, Clark PI, Joel SP, et al: A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. J Clin Oncol 7:1333-1340, 1989
40. Chen C-L, Fuscoe J, Liu Q, et al: Relationship between cytotoxicity and site-specific DNA recombination after in vitro exposure of leukemia cells to etoposide. J Natl Cancer Inst 88:1840-1847, 1996
41. Karp J, Smith M: Modifying risks of secondary leukemias: Is drug scheduling important? [comment]. J Natl Cancer Inst 88:1787-1789, 1996 (editorial)
42. Fisher B, Rockette H, Fisher E, et al: Leukemia in breast cancer patients following adjuvant chemotherapy or postoperative radiation: The NSABP experience. J Clin Oncol 3:1640-1658, 1985
43. Boice J, Greene M, Killen J, et al: Leukemia and preleukemia after adjuvant treatment of gastrointestinal cancer with semustine (methyl-CCNU). N Engl J Med 309:1079-1084, 1983
44. Coleman C, Kaplan H, Cox R, et al: Leukaemias, non-Hodgkin's lymphomas and solid tumours in patients treated for Hodgkin's disease. Cancer Surv 1:734-744, 1982
45. Coltman C, Dixon D: Second malignancies complicating Hodgkin's disease: A Southwest Oncology Group 10-year followup. Cancer Treat Rep 66:1023-1033, 1982
46. Tester W, Kinsella T, Waller B, et al: Second malignant neoplasms complicating Hodgkin's disease: The National Cancer Institute experience. J Clin Oncol 2:762-769, 1984
47. Haas J, Kittelmann B, Mehnert W, et al: Risk of leukaemia in ovarian tumour and breast cancer patients following treatment by cyclophosphamide. Br J Cancer 55:213-218, 1987
48. Cuzick J, Erskine S, Edelman D, et al: A comparison of the incidence of the myelodysplastic syndrome and acute myeloid leukemia following melphalan and cyclophosphamide treatment for myelomatosis. Br J Cancer 55:523-529, 1987
49. Curtis R, Boice J, Moloney W, et al: Leukemia following chemotherapy for breast cancer. Cancer Res 50:2741-2746, 1990
50. Valagussa P, Moliterni A, Terenziani M, et al: Second malignancies following CMF-based adjuvant chemotherapy in resectable breast cancer [see comments]. Ann Oncol 5:803-808, 1994
51. Tallman MS, Gray R, Bennett JM, et al: Leukemogenic potential of adjuvant chemotherapy for early-stage breast cancer: The Eastern Cooperative Oncology Group experience [see comments]. J Clin Oncol 13:1557-1563, 1995
52. Holdener EE, Nissen-Meyer R, Bonadonna G, et al: Second malignant neoplasms in operable carcinoma of the breast. Recent Results Cancer Res 96:188-196, 1984
53. Diamandidou E, Buzdar AU, Smith TL, et al: Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy: The University of Texas M.D. Anderson Cancer Center experience. J Clin Oncol 14:2722-2730, 1996
54. Scaradavou A, Heller G, Sklar CA, et al: Second malignant neoplasms in long-term survivors of childhood rhabdomyosarcoma. Cancer 76:1860-1867, 1995
55. Miser J, Krailo M, Smith M, et al: Secondary leukemia (SL) or myelodysplastic syndrome (MDS) following therapy for Ewing's sarcoma (ES). Proc Am Soc Clin Oncol 16:1863, 1997 (abstr)
56. Kushner BH, Cheung NKV, Kramer K, et al: Neuroblastoma and treatment-related myelodysplasia/leukemia: The Memorial Sloan-Kettering Cancer Center (MSKCC) experience. Proc Am Soc Clin Oncol 17:2041, 1998 (abstr)
57. Smith M, McCaffrey R, Karp J: The secondary leukemias: Challenges and directions. J Natl Cancer Inst 88:407-418, 1996
58. Ben-Yehuda D, Krichevsky S, Caspi O, et al: Microsatellite instability and p53 mutations in therapy-related leukemia suggest mutator phenotype. Blood 88:4296-4303, 1996